I am a bit confused.. they already did this utility study in Oct 2021. Why repeat it? I also don't like the conclusion mentioned here about further studies. Is another economics study also needed?
Conclusion PromarkerD could increase adoption of renoprotective interventions in patients at high risk for renal decline and lower the likelihood of aggressive treatment in those at low risk. Further studies are needed to assess patient outcomes with PromarkerD in real-world practice. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271740
3Q cash, hopefully enough time to release some positive news about FDA submission before cap raise, SP not looking healthy - Richard please be more transparent about what is going on with FDA & US rollout.
PIQ Price at posting:
88.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)